Coherus BioSciences Inc (NAS:CHRS)
$ 1.76 -0.06 (-3.3%) Market Cap: 201.92 Mil Enterprise Value: 429.62 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc at Barclays Global Healthcare Conference Transcript

Mar 13, 2019 / 12:00PM GMT
Release Date Price: $14.84 (-0.67%)
Douglas Dylan Tsao
Barclays Bank PLC, Research Division - Former VP

Hi. Good morning. My name's Doug Tsao from Barclays. To kick start the proceedings for the day, we have with us Jean Viret, CFO from Coherus Biosciences; and also David, who heads VP IR and Corporate Communications, Corporate Affairs. So Jean Viret, over to you, please.

Jean;FrÃ;dÃ;ric Viret
Coherus BioSciences, Inc. - CFO

©© -

Thank you, Doug Tsao, and welcome, everyone. I want to thank our friends at Barclays for inviting us again this year at their health care conference. Today, I'll be making forward-looking statements. These forward-looking statements have certain risks and uncertainties that are described in our Form 10-K that was just submitted to the SEC. So I encourage you to look at the uncertainties submitted in this document.

Today, I'm going to cover 3 areas. First, I'm going to do a company summary. Second, I'll also spend quite a bit of time on our UDENYCA launch. UDENYCA is our pegfilgrastim and biosimilar. And lastly, I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot